NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted EBIT Margin of 1921.71% for Q1 2026, up 99.07% sequentially from 206187.5% in Q4 2025, and up 39276.0% YoY from N/an in Q1 2025.
NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported EBIT Margin for 4 years, with the latest figure at 1921.71% in Q1 2026.
- Quarterly EBIT Margin rose 39276.0% year-over-year to 1921.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 953.59% (down 55111.0% YoY) and the FY2025 annual result came in at 1002.9%, down 61599.0% from the prior year.
- EBIT Margin rose to 1921.71% in Q1 2026 per NAMS's latest filing, from 206187.5% in the prior quarter.
- Over five years, EBIT Margin peaked at 85.89% in Q3 2024 and troughed at 206187.5% in Q4 2025.
- A 4-year average of 18779.11% and a median of 2306.93% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin soared 602193 bps in 2024, then slumped 20584903 bps in 2025.
- Over 4 years, EBIT Margin stood at 6360.4% in 2023, then soared by 95 bps to 338.47% in 2024, then sank by 60818 bps to 206187.5% in 2025, then jumped by 99 bps to 1921.71% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 1921.71%, 206187.5%, and 15845.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | -1,752.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,752.61% |
| Mar 31, 2026 | -1,921.71% |
| Dec 31, 2025 | -206,187.50% |
| Sep 30, 2025 | -15,845.69% |
| Jun 30, 2025 | -186.13% |
| Mar 31, 2025 | -2,314.47% |
| Dec 31, 2024 | -338.47% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -2,306.93% |
| Mar 31, 2024 | -3,960.17% |
| Dec 31, 2023 | -6,360.40% |
| Sep 30, 2023 | -1,685.07% |
| Jun 30, 2023 | -2,474.20% |
| Mar 31, 2023 | -461.85% |